 Antifungal Agents
"Antifungal Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues.
| Descriptor ID |
D000935
|
| MeSH Number(s) |
D27.505.954.122.136
|
| Concept/Terms |
Antifungal Agents- Antifungal Agents
- Agents, Antifungal
- Therapeutic Fungicides
- Fungicides, Therapeutic
|
Below are MeSH descriptors whose meaning is more general than "Antifungal Agents".
Below are MeSH descriptors whose meaning is more specific than "Antifungal Agents".
This graph shows the total number of publications written about "Antifungal Agents" by people in this website by year, and whether "Antifungal Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1996 | 1 | 0 | 1 | | 1997 | 1 | 0 | 1 | | 1998 | 1 | 1 | 2 | | 1999 | 0 | 2 | 2 | | 2001 | 1 | 0 | 1 | | 2003 | 1 | 3 | 4 | | 2004 | 1 | 3 | 4 | | 2005 | 3 | 2 | 5 | | 2006 | 1 | 1 | 2 | | 2007 | 2 | 1 | 3 | | 2008 | 1 | 2 | 3 | | 2009 | 1 | 3 | 4 | | 2010 | 1 | 0 | 1 | | 2011 | 3 | 2 | 5 | | 2012 | 3 | 3 | 6 | | 2013 | 4 | 2 | 6 | | 2014 | 4 | 5 | 9 | | 2015 | 2 | 4 | 6 | | 2016 | 4 | 4 | 8 | | 2017 | 2 | 2 | 4 | | 2018 | 0 | 2 | 2 | | 2019 | 3 | 1 | 4 | | 2020 | 4 | 2 | 6 | | 2021 | 0 | 1 | 1 | | 2022 | 1 | 5 | 6 | | 2023 | 0 | 6 | 6 | | 2024 | 1 | 1 | 2 | | 2025 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Antifungal Agents" by people in Profiles.
-
Pham HT, Castelino RL, Kiser TH, Truong-Nguyen KH, Tran MH. Empirical versus pre-emptive antifungal therapies for invasive fungal infections in critically ill patients. BMC Infect Dis. 2025 Mar 22; 25(1):395.
-
Okurut S, Boulware DR, Manabe YC, Tugume L, Skipper CP, Ssebambulidde K, Rhein J, Musubire AK, Akampurira A, Okafor EC, Olobo JO, Janoff EN, Meya DB. Impact of cerebrospinal fluid leukocyte infiltration and activated neuroimmune mediators on survival with HIV-associated cryptococcal meningitis. PLoS Negl Trop Dis. 2025 Feb; 19(2):e0012873.
-
Bucayu RFT, Boge CLK, Yildirim I, Avil?s-Robles M, Vora SB, Berman DM, Sharma TS, Sung L, Castagnola E, Palazzi DL, Danziger-Isakov L, Yin DE, Roilides E, Maron G, Tribble AC, Soler-Palacin P, L?pez-Medina E, Romero J, Belani K, Arrieta AC, Carlesse F, Nolt D, Halasa N, Dulek D, Rajan S, Muller WJ, Ardura MI, Pong A, Gonzalez BE, Salvatore CM, Huppler AR, Aftandilian C, Abzug MJ, Chakrabarti A, Green M, Lutsar I, Knackstedt ED, Johnson SK, Steinbach WJ, Fisher BT, Wattier RL. Transition to Enteral Triazole Antifungal Therapy for Pediatric Invasive Candidiasis: Secondary Analysis of a Multicenter Cohort Study Conducted by the Pediatric Fungal Network. J Pediatric Infect Dis Soc. 2024 Dec 30; 13(12):633-638.
-
Kim U, Perzia B, Kulkarni P, Rajiniganth M, Sundar B, Robin AL, Garg Shukla A, Maeng MM. COVID-19-associated rhino-orbito-cerebral mucormycosis: a single center prospective study of 264 patients. Orbit. 2025 Feb; 44(1):24-33.
-
Okurut S, Boulware DR, Okafor E, Rhein J, Kajumbula H, Bagaya BS, Bwanga F, Olobo JO, Manabe YC, Meya DB, Janoff EN. Divergent neuroimmune signatures in the cerebrospinal fluid predict differential gender-specific survival among patients with HIV-associated cryptococcal meningitis. Front Immunol. 2023; 14:1275443.
-
Alanazi AH, Chastain DB, Rudraraju M, Parvathagiri V, Shan S, Lin X, Henao-Mart?nez AF, Franco-Paredes C, Narayanan SP, Somanath PR. A multi-arm, parallel, preclinical study investigating the potential benefits of acetazolamide, candesartan, and triciribine in combination with fluconazole for the treatment of cryptococcal meningoencephalitis. Eur J Pharmacol. 2023 Dec 05; 960:176177.
-
Wattier RL, Bucayu RFT, Boge CLK, Ross RK, Yildirim I, Zaoutis TE, Palazzi DL, Vora SB, Castagnola E, Avil?s-Robles M, Danziger-Isakov L, Tribble AC, Sharma TS, Arrieta AC, Maron G, Berman DM, Yin DE, Sung L, Green M, Roilides E, Belani K, Romero J, Soler-Palacin P, L?pez-Medina E, Nolt D, Bin Hussain IZ, Muller WJ, Hauger SB, Halasa N, Dulek D, Pong A, Gonzalez BE, Abzug MJ, Carlesse F, Huppler AR, Rajan S, Aftandilian C, Ardura MI, Chakrabarti A, Hanisch B, Salvatore CM, Klingspor L, Knackstedt ED, Lutsar I, Santolaya ME, Shuster S, Johnson SK, Steinbach WJ, Fisher BT. Adjunctive Diagnostic Studies Completed Following Detection of Candidemia in Children: Secondary Analysis of Observed Practice From a Multicenter Cohort Study Conducted by the Pediatric Fungal Network. J Pediatric Infect Dis Soc. 2023 Sep 27; 12(9):487-495.
-
Henao-Mart?nez AF, Chastain DB, Thompson GR. Treatment pathways, switches, and inappropriate treatment during invasive pulmonary aspergillosis: real-world experiences from a global research network study. Antimicrob Agents Chemother. 2023 10 18; 67(10):e0072123.
-
Henao-Mart?nez AF, Corbisiero MF, Salter I, Chastain DB, Thompson GR. Invasive pulmonary aspergillosis real-world outcomes: Clinical features and risk factors associated with increased mortality. Med Mycol. 2023 Aug 02; 61(8).
-
Chastain DB, White BP, Tu PJ, Chan S, Jackson BT, Kubbs KA, Bandali A, McDougal S, Henao-Mart?nez AF, Cluck DB. Candidemia in Adult Patients in the ICU: A Reappraisal of Susceptibility Testing and Antifungal Therapy. Ann Pharmacother. 2024 Mar; 58(3):305-321.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|